Mobile App Boosts HIV Treatment Adherence in Trial
A randomised trial found a smartphone intervention lowered detectable HIV viral load among sexual minority men who use stimulants.
Updated on Nov. 8, 2026 in Substance Abuse
A randomised controlled trial published in eClinicalMedicine tested a mobile health application for antiretroviral therapy adherence among sexual minority men with HIV who screened positive for stimulant use disorder. The application reduced detectable HIV-1 viral load at six months compared with a website control condition.
Why it matters
Methamphetamine and other stimulants are a prominent driver of the HIV epidemic, and stimulant use makes adherence harder, raising the likelihood of detectable viral load and onward transmission risk. The findings suggest a digital tool may help address this gap in care for affected men across the country.
The trial enrolled 286 participants and used a detectable viral load threshold of more than 300 copies per millilitre, with the application significantly lowering the odds of detectable viral load at six months versus a website control. Up to one in three sexual minority men who acquire HIV in the United States report persistent methamphetamine use, and the 12-month outcome has not been reported.
The players
eClinicalMedicine
A peer-reviewed open-access medical journal published by The Lancet group that released the trial report.
The details
The START application integrates positive psychological intervention skills and was designed to improve adherence whether or not participants were ready to reduce stimulant use. Participants were randomised to the app or to a website providing referrals to care resources, with remote blood samples collected at baseline, six months, and 12 months.
Timeline
Baseline: initial remote blood sample collected for viral load measurement.
Six months: primary outcome measured and application effect on viral load assessed.
12 months: final remote blood sample collected for viral load measurement.
Health Landscape
Earlier adherence interventions for people with HIV who use methamphetamine produced moderate gains in self-reported adherence but inconsistent effects on objective biomarkers. This trial measures viral load directly, testing whether a digital intervention can move the clinical marker that earlier studies left uncertain.
For people living with HIV who use stimulants, a smartphone tool may offer a practical way to support daily medication routines. The results point to a potential option for improving treatment consistency, though it is not yet a standard clinical service.
The takeaway
Stimulant use is a modifiable barrier to HIV viral suppression, and digital tools that address adherence directly may complement existing care. Anyone managing HIV treatment alongside substance use should discuss adherence support options with their clinician.
Further reading
Explore more on Substance Abuse to see how stimulant use shapes treatment outcomes across the United States.
Source note: This article includes information reported by EATG.
